✕
Transposon Therapeutics, Inc. Science Pipeline Team News / Literature Connect
✕
Decorative image.

‹ Pipeline › TPN-101

AD

Alzheimer’s Disease


About AD

Why TPN-101?
✕

Alzheimer’s Disease (AD)


About AD
AD is a neurodegenerative disease and the most common cause of dementia. Difficulty remembering recent events occurs early followed by problems with language, disorientation, mood swings, loss of motivation, self-neglect or behavioral issues. Loss of bodily functions ultimately leads to death in 3 to 12 years.

✕

Alzheimer’s Disease (AD)


Why TPN-101?
LINE-1 targeted therapy, such as TPN-101, has the potential to reduce innate immune activation, improve cognition and reduce neurodegeneration in AD.

Results from the TPN-101 Phase 2a studies may be relevant to AD as proteinopathies common to PSP and C9-ALS/FTD are also found in AD. AD and PSP are tau-related diseases, and increased TDP-43 is found in C9-ALS/FTD and approximately 50% of AD patients with worsening cognition. Most importantly, reductions in CSF levels of NfL and osteopontin observed following TPN-101 treatment may translate to therapeutic benefit in AD as elevated CSF NfL is associated with disease progression, and elevated osteopontin is associated with cognitive decline.

Clinical Trial Information

Coming soon